« Back
Home /
XY028-140

XY028-140

Item no.	HY-138946-50mg
Manufacturer	MedChem Express
CASRN	2229974-83-6
Amount	50 mg
Quantity options	100 mg 10 mg 25 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitor
Specific against	other
Purity	98.52
Citations	[1]Jian Jin, et al. Compositions and methods for treating cdk4/6-mediated cancer. WO2018106870A1.\|[2]Xuewei Wu, et al. Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders. Nat Cancer 2, 429-443 (2021).
Smiles	O=C1C2=C(C(N1C3C(NC(CC3)=O)=O)=O)C(NCC(N4CCN(CC4)C5=CN=C(NC6=NC(N(C7CCCC7)C(C(C(C)=O)=C8C)=O)=C8C=N6)C=C5)=O)=CC=C2
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	CDK; PROTACs
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	760.80
Product Description	XY028-140 is a PROTAC connected by ligands for Cereblon and CDK. XY028-140 inhibits both CDK4/6 expression and CDK4/6 activity in cancer cells[1].
Manufacturer - Research Area	Cancer
Solubility	DMSO: 5.56 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturer - Pathway	Cell Cycle/DNA Damage; PROTAC
Isoform	CDK4; CDK6; Cereblon
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-138946-50mg-safety-datasheet.pdf